Home RYBREVANT® + LAZCLUZE® Demonstrates Prolonged Clinical Benefit as First-Line Treatment for Atypical EGFR-Mutated Non-Small Cell Lung Cancer

RYBREVANT® + LAZCLUZE® Demonstrates Prolonged Clinical Benefit as First-Line Treatment for Atypical EGFR-Mutated Non-Small Cell Lung Cancer

May 30, 2026 02:00 CST Updated 08:15